Research
Hormonal
Tirzepatide treatment was associated with lower hazards of major adverse cardiovascular events (MACEs) compared to GLP-1 RA (AHR, 0.80; 95% CI, 0.71-0.91).
Tirzepatide may be a preferable treatment option for reducing cardiovascular risks in patients with type 2 diabetes.
StrongSupportsmedium confidence
Tirzepatide treatment was associated with lower hazards of MACEs (AHR, 0.80; 95% CI, 0.71-0.91).
Why this rating
Based on a large retrospective cohort study design.
Source
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes
Min‐Hsiang Chuang et al. · JAMA Network Open · 2024
cohort · n=140308Cited 106×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →